IL-10- and IL-13-Biased T Cell Responses to SARS-CoV-2 Vaccination in Diabetes.

IL-10- and IL-13-Biased T Cell Responses to SARS-CoV-2 Vaccination in Diabetes.

Publication date: Dec 01, 2025

Type 1 and type 2 diabetes are associated with increased severity and mortality from respiratory virus infections. Vaccination in the general population significantly reduces the risk of severe respiratory viral infection and triggers a strong, polyfunctional, and lasting T cell response in healthy individuals. However, vaccine effectiveness in people with type 1 diabetes is unclear. Here, we studied the magnitude and functional characteristics of vaccine-specific CD4 and CD8 T cell responses to vaccination in people with type 1 and type 2 diabetes and compared them to those of people living without diabetes, using the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as a model. We found defects in both CD4 and CD8 T cell memory maintenance and the functionality of the vaccine-specific T cells in people with diabetes compared with people without. In those individuals with type 1 and type 2 diabetes who harbored detectable vaccine-specific T cells, they displayed an unfocused, tolerogenic phenotype characterized by increased expression of IL-10 and IL-13 compared with people without diabetes. These results have implications for vaccination strategies for people with diabetes.

Open Access PDF

Concepts Keywords
Cd4 Adult
Diabetes Aged
Healthy CD4-Positive T-Lymphocytes
Vaccination CD8-Positive T-Lymphocytes
Viral COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Female
Humans
IL10 protein, human
IL13 protein, human
Immunologic Memory
Interleukin-10
Interleukin-10
Interleukin-13
Interleukin-13
Male
memory
Middle Aged
SARS-CoV-2
SARS‐CoV‐2
T cells
type 1 diabetes
Vaccination
vaccination

Semantics

Type Source Name
drug DRUGBANK Interleukin-10
disease MESH type 2 diabetes
disease MESH virus infections
disease MESH type 1 diabetes
disease MESH severe acute respiratory syndrome
drug DRUGBANK Ibuprofen
disease MESH Infectious Disease
pathway REACTOME Infectious disease
disease MESH NHS
pathway REACTOME Metabolism
pathway REACTOME Digestion
pathway REACTOME Reproduction
disease MESH SARS CoV 2 infection
disease MESH Influenza
drug DRUGBANK Coenzyme M
disease MESH hepatitis
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Tretamine
disease MESH included
disease MESH T2D4
disease MESH obesity
pathway REACTOME Influenza Infection
disease MESH infections
drug DRUGBANK BCG vaccine
drug DRUGBANK Isoxaflutole
drug DRUGBANK Trestolone
disease MESH hyperglycemia
disease MESH inflammation
disease MESH diabetes mellitus
disease MESH malignancy
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Nitrogen
drug DRUGBANK Water
drug DRUGBANK Streptomycin
disease MESH APC
disease MESH PBS
disease MESH Pneumonia
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH vaccinia
drug DRUGBANK Methylergometrine
disease MESH Overweight
disease MESH Tar
disease MESH Post COVID Conditions
disease MESH Myelopathy

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *